FDA Grants Priority Review to BeOne’s New Drug for Aggressive Blood Cancer

The FDA has accepted and fast-tracked BeOne Medicines’ new drug sonrotoclax for adults with relapsed or refractory mantle cell lymphoma, a rare and fast-growing blood cancer.